CytoDyn DNA Vaccine Shows Low-Dose Protection From Bird Flu

CytoDyn has completed analysis of its prospective, placebo-controlled study with mice to compare nine variations of experimental DNA vaccines for the bird flu.

Three of the vaccines given at a relatively low dose caused mice to develop antibodies against the bird flu at a significant level, CytoDyn said.

According to the company, the three vaccines included: a vaccine obtained from the University of Massachusetts Medical School (UMMS); a vaccine based on the UMMS product and enhanced using the latest method of improving DNA vaccines; and a similarly enhanced bird flu vaccine from a company that makes DNA vaccines for protecting animals.

All three appeared to be equally effective in terms of the quantity of antibodies produced, although, without enhancement, the UMMS vaccine appeared to be somewhat less potent in other respects, the company added.